Clinical Trials Browser

INDUSTRY × zimberelimab × Clear all

NCT05633667 2026-03-17

VELOCITY-Lung

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03547973 2026-03-16

TROPHY U-01

Phase 2 Recruiting

827 enrolled 1 FDA

Metastatic Urothelial Cancer

NCT04736173 2026-03-09

ARC-10

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05568095 2026-03-04

STAR-221

Phase 3 Active not recruiting

Gastrointestinal

Adenocarcinoma Of Esophagus, Stomach Neoplasms

NCT06727565 2026-03-02

VELOCITY-HNSCC

Phase 2 Active not recruiting

Squamous Cell Carcinoma of Head and Neck

NCT04104672 2026-02-27

ARC-8

Phase 1 Active not recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT05329766 2026-02-27

EDGE-Gastric

Phase 2 Active not recruiting

Gastrointestinal

Adenocarcinoma Of Esophagus, Stomach Neoplasms

NCT05536141 2026-02-27

ARC-20

Phase 1 Recruiting

Erythrocytosis, Familial, 4, Carcinoma, Renal Cell, Kidney Neoplasms

NCT05891171 2026-02-27

ARC-25

Phase 1 Active not recruiting

BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Ovarian Neoplasms, Stomach Neoplasms, Triple Negative Breast Neoplasms

NCT06759649 2026-02-27

A Clinical Trial to Assess COM503 in Participants With Advanced Solid Malignancies

Phase 1 Recruiting

Neoplasms

NCT05502237 2026-01-30

STAR-121

Phase 3 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT05840224 2026-01-28

Study of GS-4528 in Adults With Solid Tumors

Phase 1 Active not recruiting

Other solid neoplasm

Solid Tumor

NCT05007782 2025-12-29

Study of Denikitug (GS-1811) Given Alone or With Zimberelimab in Adults With Advanced Solid Tumors

Phase 1 Recruiting

Other solid neoplasm

Advanced Solid Tumor

NCT04854499 2025-11-19

ELEVATE HNSCC

Phase 2 Terminated

193 enrolled 27 charts

Squamous Cell Carcinoma of Head and Neck

NCT04660812 2025-10-20

ARC-9

Phase 1/2 Completed

Gastrointestinal

Colorectal Neoplasms

NCT06082960 2025-09-10

Study of GS-9911 With or Without Antibody Treatment for Adults With Solid Tumors

Phase 1 Active not recruiting

Other solid neoplasm

Solid Tumors

NCT04772989 2025-08-28

ARC-12

Phase 1 Completed

DermatologicGastrointestinalGynecologicLymphoidPlasma cellThoracic

Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Esophageal Neoplasms, Lymphoma, Non-Hodgkin, Melanoma, Multiple Myeloma, Stomach Neoplasms, Lymphoma, Large B-Cell, Diffuse

NCT04381832 2025-07-22

Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer

Phase 1/2 Completed

Prostatic Neoplasms, Castration-Resistant

NCT06532565 2025-05-16

Study of GS-2121 Given Alone or in Combination in Adults With Advanced Solid Tumors

Phase 1 Recruiting

Other solid neoplasm

Advanced Solid Tumors

NCT05177770 2025-05-08

Study of SRF617 With AB928 (Etrumadenant) and AB122 (Zimberelimab) in Patients With Metastatic Castration Resistant Prostate Cancer

Phase 2 Terminated

16 enrolled 10 charts

Neoplasms, Prostatic Neoplasms

NCT03628677 2025-02-04

A Study to Evaluate the Safety and Tolerability of AB154 in Participants With Advanced Malignancies

Phase 1 Completed

Other solid neoplasm

Solid Tumor, Unspecified, Adult

NCT03846310 2024-12-09

ARC-4

Phase 1 Completed

Carcinoma, Non-Small-Cell Lung

NCT04087018 2024-09-19

Study to Evaluate Safety and Clinical Activity of AB122 in Biomarker Selected Participants With Advanced Solid Tumors

Phase 1 Completed

Other solid neoplasm

Advanced Solid Tumors

NCT04747470 2024-09-03

Study to Assess the Effects of GS-3583 in Participants With Advanced Solid Tumors

Phase 1 Terminated

13 enrolled 18 charts

Other solid neoplasm

Advanced Solid Tumors

NCT06155396 2024-02-28

A Study of RC48-ADC Combination With Zimberelimab Injection Therapies at Least First-line Platinum-containing Standard Therapy Failed With Recurrent or Metastatic Cervical Cancer

Phase 2 Recruiting

Uterine Cervical Neoplasms

NCT05909436 2023-06-18

Immuno-Oncology Drugs GLS-012 Alone & in Combination GLS-010 Treating With Advanced Patients Solid Tumors

Phase 1/2 Recruiting

Other solid neoplasm

Solid Tumor

NCT05798819 2023-04-05

A Study of GLS-010 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer

Phase 3 Not yet recruiting

Recurrence

NCT03972722 2019-06-05

CC

Phase 2 Unknown

Uterine Cervical Neoplasms